KIORA PHARMACEUTICALS INC — Director's Dealing 2017

Jun 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2017-06-14

Reporting Person: FROM STEPHEN (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-14	Common Stock	P	60000	—	Acquired	259965	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-14	Warrants (right to buy)	$1.50	P	60000	Acquired	2022-06-14	Common Stock (60000)	Direct

Footnotes

F1: The reported securities were purchased by the reporting person for a combined purchase price of $1.50 per share of common stock and warrant in connection with the Issuer's public offering that closed on June 14, 2017. Each warrant will be exercisable during the period commencing on June 14, 2017 and ending on June 14, 2022 at an exercise price of $1.50.